1. A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study. Issue 3 (1st March 2015) Authors: Kunos, Charles; Deng, Wei; Dawson, Dawn; Lea, Jayanthi S.; Zanotti, Kristine M.; Gray, Heidi J.; Bender, David P.; Guaglianone, Perry P.; Carter, Jori S.; Moore, Kathleen N. Journal: International journal of gynecological cancer Issue: Volume 25:Issue 3(2015:Mar.) Page Start: 484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix. Issue 3 (March 2015) Authors: Kunos, Charles; Deng, Wei; Dawson, Dawn; Lea, Jayanthi S.; Zanotti, Kristine M.; Gray, Heidi J.; Bender, David P.; Guaglianone, Perry P.; Carter, Jori S.; Moore, Kathleen N. Journal: International journal of gynecological cancer Issue: Volume 25:Issue 3(2015:Mar.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗